Roche’s Gazyva wins EU nod for adults with active lupus nephritis
Roche (RHHBY) announced that the European Commission approved Gazyva/Gazyvaro (obinutuzumab) on 9 December 2025 for adults with active…
Roche lupus drug cuts disease activity in phase III
Roche (OTCQX: RHHBY) announced NEJM publication of phase III ALLEGORY data showing Gazyva/Gazyvaro (obinutuzumab) plus standard therapy significantly…
Roche’s Gazyva Meets Phase III SLE Endpoints at 52 Weeks
Roche (RHHBY) announced on 3 November 2025 that the phase III ALLEGORY study…